scholarly journals Dupilumab improves health‐related quality of life in severe chronic rhinosinusitis with nasal polyps

Allergy ◽  
2022 ◽  
Author(s):  
Stella E. Lee ◽  
Claire Hopkins ◽  
Joaquim Mullol ◽  
Jérôme Msihid ◽  
Isabelle Guillemin ◽  
...  
2021 ◽  
Vol 147 (2) ◽  
pp. AB133
Author(s):  
Jorge Maspero ◽  
Carl Philpott ◽  
Peter Hellings ◽  
Claire Hopkins ◽  
Martin Wagenmann ◽  
...  

2019 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
A. Khan ◽  
T.M.T. Huynh ◽  
G. Vandeplas ◽  
V.N. Joish ◽  
L.P. Mannent ◽  
...  

2015 ◽  
pp. 150526140002000
Author(s):  
Al-Rahim R Habib ◽  
Jane A Buxton ◽  
Joel Singer ◽  
Pearce G Wilcox ◽  
Amin R Javer ◽  
...  

2021 ◽  
Vol 4 (4) ◽  
pp. 58-65
Author(s):  
E.S. Lourijsen ◽  
M. Vleming ◽  
S. Reitsma ◽  
W.J. Fokkens

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) afflicts 2-4% of the population and comes with a long time burden of disease and high societal costs. The current treatment consists of medical treatment alone or in combination with endoscopic sinus surgery. No consensus exists on the right timing and extent of disease that warrants surgery. Furthermore, there is lack of clinical knowledge about the benefit of surgery over medication only. The current study evaluates the clinical effectiveness and cost-effectiveness of endoscopic sinus surgery in addition to medical treatment versus medication alone in the adult patient group with nasal polyps (CRSwNP). Methods: The PolypESS trial is designed as a prospective, randomised, multicentre trial in adult patients with CRSwNP selected for primary or revision endoscopic sinus surgery by their otorhinolaryngologist. Patients are randomly assigned to endoscopic sinus surgery in addition to medication or medical therapy only. This paper details the statistical analysis plan (SAP) of this trial and was submitted before outcome data were available. Results: The primary outcome of the trial is disease-specific Health-Related Quality of Life quantified by the SNOT-22 at 12-months follow-up. Secondary outcomes consist of generic and disease-specific Health-Related Quality of Life, objective signs of disease and adverse events of treatment. Subgroup analyses will be performed to verify if treatment effects differ among patient phenotypes. Analyses will be completed according to this pre-specified SAP. The main analysis will be performed as a standard ITT analysis. Discussion: The PolypESS trial will show whether addition of endoscopic sinus surgery to medical treatment improves the disease-specific Health-Related Quality of Life quantified by the SNOT-22 at 12-months follow-up. Unforeseen deviations from the SAP at the time of analysis will be motivated and discussed in the final publication of the primary outcome of this study.


2021 ◽  
pp. 194589242110136
Author(s):  
Amarbir S. Gill ◽  
Shaelene Ashby ◽  
Gretchen M. Oakley ◽  
Toby O. Steele ◽  
Dennis Menjivar ◽  
...  

Background Medical comorbidities are commonly encountered in chronic rhinosinusitis (CRS) and may impact both physical function and patient reported health-related quality-of-life (HRQOL). The functional comorbidity index (FCI) is designed to elucidate the role of comorbidities on functional prognosis. The objective of this study was to understand the impact of comorbidities known to impact physical function on baseline HRQOL using the FCI. Methodology: Patients meeting diagnostic criteria for CRS were prospectively enrolled in a cross-sectional study. Responses from the Sinonasal Outcomes Test-22 (SNOT-22), a measure of patient HRQOL, as well as the Lund-Kennedy and Lund-Mackay scores were recorded at enrollment. FCI was calculated retrospectively using the electronic medical record. Information was collected and compared for patients without (CRSsNP) and with nasal polyps (CRSwNP) using chi-square and t-tests. Spearman’s correlations, followed by multivariate regression analysis, were used to assess the association between FCI and SNOT-22 scores. Results One hundred and three patients met inclusion criteria for analysis. There were no significant differences in age, gender, and SNOT-22 scores between patients with CRSsNP and those with CRSwNP. FCI was significantly and independently associated with worse SNOT-22 scores ( P = .012). FCI did not correlate with endoscopy and computed tomography scores. The mean FCI for patients with CRSsNP and CRSwNP was 2.02 and 2.24, respectively, and did not differ significantly between the two cohorts ( P = .565). Conclusions Major medical comorbidities known to affect physical function are associated with worse SNOT-22 scores in patients with CRS as measured by the FCI.


Sign in / Sign up

Export Citation Format

Share Document